Thermo Fisher Scientific Inc

Stock-pickers find value in times of volatility and continue to purchase and hold high-quality names.

The future's bright for these 29 companies. Grab the shades.

Continued technology advancements and market expansion support Illumina's narrow moat.

A group of top managers continue to keep looking for good investment opportunities, while taking full advantage of a rising (and potentially overvalued) market to book some gains.

Remarkable performances amid a remarkable year.

It appears that the corporate-bond market believes Friday's jobs report was high enough to suggest an advancing economy, but not so strong as to prompt a Fed taper.

A handful of analyst-recommended moderate-allocation funds have proved their mettle in good times and bad.

We are seeing an increase in idiosyncratic catalysts that are specific to an individual issuer as opposed to industry factors that affect an entire sector.

Widening investment-grade credit spreads and rising interest rates lead to losses.

Investors should keep their expectations in check with few asset classes looking particularly attractive and complacency in the marketplace, says Allocation Fund Manager of the Year David Giroux of T. Rowe Price Capital Appreciation.

These skippers shone amid a challenging market environment.

A lot of companies are very well positioned regardless of how the fiscal cliff gets resolved, as long as it gets resolved, says Morningstar's Heather Brilliant.

Success in 2012 took many forms.

Election and potential sequestration emerge as key topics for health care.

The decline in the equity markets created plenty of buying opportunities in the most recent period, but some of our managers seem to have jumped into energy stocks sooner than they should have.

Even if the NIH is drastically cut, we don't see a doomsday scenario for these companies, and some of the industry's stronger players are now trading at attractive valuations.

Five-star-rated Devon Energy has been the standout buy so far for our top managers.

Over the course of the next month, we expect a number of events may cause a disruption in the calm we have experienced.

A global reach and broad product offerings underlie the company's narrow moat.

While we remain bullish on the sector, health-care growth depends on the economy.